- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Per-Se appoints new CEO following Ritchie departure
Per-Se Technologies has appointed Philip Pead president and CEO following the abrupt departure of Allen Ritchie. Pead also assumes Ritchie's spot on the company's board of directors. Pead joined Per-Se in 1997 and most recently held the
Per-Se Technologies has appointed Philip Pead president and CEO following the abrupt departure of Allen Ritchie. Pead also assumes Ritchie's spot on the company's board of directors. Pead joined Per-Se in 1997 and most recently held the positions of executive vice president and COO for the firm. Per-Se provides business management services to physicians and claims to support 35,000 physicians and 2000 healthcare organizations.
© 2000 Miller Freeman Inc.
11/29/00, Issue # 117, page 5.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
